Canine PA antibody and antigen (recombinant protein)
Diagnostic anti-Canine PA antibodies pairs and antigen for animal health (animal Dog/Canine liver disease, inflammation, or tissue death) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT
Go to Neurodegenerative diseases diagnostics products collection >>
Product information
Catalog No. | Description | US $ Price (per mg) |
---|---|---|
GMP-CAN-PA-Ag01 | Recombinant Canine PA protein | 3090 |
GMP-CAN-PA-Ab01 | Anti-Canine PA mouse monoclonal antibody (mAb) | 1953 |
GMP-CAN-PA-Ab02 | Anti-Canine PA mouse monoclonal antibody (mAb) | 1953 |
GMP-CAN-PA-Ab03 | Anti-Canine PA human monoclonal antibody (mAb) | 1953 |
GMP-CAN-PA-Ab04 | Anti-Canine PA human monoclonal antibody (mAb) | 1953 |
Size: 1mg | 10mg | 100mg
Product Description
Cat No. of Products | GMP-CAN-PA-Ag01 |
Product Name | Recombinant Canine PA protein |
Target/Biomarker | Canine Prealbumin (PA) |
Expression platform | E.coli |
Isotypes | Recombinant Antigen |
Bioactivity validation | Anti-Canine Prealbumin antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in PA level test of animal Dog/Canine with liver disease, inflammation, or tissue death. |
Tag | His |
Products description | Recombinant Canine PA protein was expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. of Products | GMP-CAN-PA-Ab01, GMP-CAN-PA-Ab02 |
Product Name | Anti-Canine PA mouse monoclonal antibody (mAb) |
Target/Biomarker | Canine Prealbumin (PA) |
Expression platform | CHO |
Isotypes | Mouse IgG |
Bioactivity validation | Recombinant Canine Prealbumin antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-PA antibodies in PA level test of animal Dog/Canine with liver disease, inflammation, or tissue death. |
Tag | mFc |
Products description | Anti-Canine PA mouse monoclonal antibody (mAb) is a monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-PA antibodies. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. of Products | GMP-CAN-PA-Ab03, GMP-CAN-PA-Ab04 |
Product Name | Anti-Canine PA human monoclonal antibody (mAb) |
Target/Biomarker | Canine Prealbumin (PA) |
Expression platform | CHO |
Isotypes | Human IgG1 |
Bioactivity validation | Recombinant Canine Prealbumin antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-PA antibodies in PA level test of animal Dog/Canine with liver disease, inflammation, or tissue death. |
Tag | hFc |
Products description | Anti-Canine PA human monoclonal antibody (mAb) is a monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-PA antibodies. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Validation Data
Click to get more Data / Case study about the product.
Target/Biomarker information
Canine Prothrombin Activation Fragment 1+2 (cPAF1+2) represents a pivotal component in the intricate web of canine hemostasis. Structurally, it emerges as a fragment resulting from the activation of prothrombin (Factor II) into thrombin (Factor IIa), a process catalyzed by various coagulation factors and platelet interactions. This activation event is central to blood clot formation, serving as the gateway to the coagulation cascade. Prothrombin, an inert precursor protein, remains quiescent in the circulation until it encounters a vascular injury. Upon such an encounter, a series of enzymatic reactions ensue, leading to the cleavage of prothrombin into two fragments: thrombin and cPAF1+2. Thrombin, the multifaceted enzyme that emerges from this process, plays a pivotal role in the formation of a stable blood clot. It accomplishes this by catalyzing the conversion of soluble fibrinogen into insoluble fibrin strands, which, in turn, compose the structural scaffold of a clot. cPAF1+2, on the other hand, assumes a different role. It does not participate directly in clot formation but serves as an indispensable marker of ongoing thrombin generation. Its presence in the bloodstream reflects the dynamic equilibrium between prothrombin activation and thrombin regulation.
About GDU
GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.
Comments
No comments yet.